Trials / Completed
CompletedNCT03863080
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Immunovant Sciences GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RVT-1401 | Subcutaneous administration of RVT-1401 |
| DRUG | Placebo | Subcutaneous administration of Placebo |
Timeline
- Start date
- 2019-05-21
- Primary completion
- 2020-10-07
- Completion
- 2020-12-21
- First posted
- 2019-03-05
- Last updated
- 2023-12-20
- Results posted
- 2023-12-20
Locations
20 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03863080. Inclusion in this directory is not an endorsement.